Related Experiment Video
Updated: Jul 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Archived M184V/I Mutation and Risk of Virological Failure After Switching to Doravirine, Lamivudine, Tenofovir
Romain Palich1, Axel Ursenbach2, Nolwenn Hall3
1Paris Cité University, Immunology and Infectious Diseases Department, Hôtel-Dieu Hospital, AP-HP, Paris, France.
Abstract:
Among 1282 virally suppressed people with HIV switching to doravirine/lamivudine/tenofovir disoproxil fumarate, 40 (3.1%) experienced virological failure (VF) during follow-up (median 81 weeks). Archived M184V/I mutation (7.4% of study population) was not significantly associated with VF after adjustment (adjusted hazard ratio 1.36; 95%CI 0.51-3.66).
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Viral Mutations
Retroviruses

